Table 2 Clinical trial drug for targeting cancer cells carrying mutp53.
From: Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Role | Drug | Disease | Phase | NCT number | Start date |
|---|---|---|---|---|---|
Restoration | APR-246 | High-grade serous ovarian cancer | Phase Ib/II | NCT02098343 | March 2014 |
Phase II | NCT03268382 | July 2017 | |||
Oesophageal carcinoma | Phase Ib/II | NCT02999893 | April 2017 | ||
AML or MDS | Phase II | NCT03931291 | September 2019 | ||
MDS | Phase III | NCT03745716 | January 2019 | ||
Myeloid malignancy | Phase I | NCT04214860 | December 2019 | ||
Myeloid neoplasms | Phase Ib/ II | NCT03588078 | September 2018 | ||
COTI-2 | Advanced or recurrent malignancies | Phase I | NCT02433626 | December 2015 | |
PC14586 | Advanced solid tumor, advanced malignant neoplasm, metastatic cancer, metastatic solid tumor | Phase I/ II | NCT04585750 | October 2020 | |
ATO | AML or MDS | Phase I | NCT03855371 | January 2018 | |
Refractory cancer, intractable cancer | Phase II | NCT04695223 | January 2021 | ||
Refractory solid tumors | Phase II | NCT04869475 | April 2021 | ||
Degradation | Ganetespib | Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer | Phase I/ II | NCT02012192 | July 2014 |
Atorvastatin | Solid tumor and relapsed AML | Phase I | NCT03560882 | July 2018 | |
Colorectal carcinoma, ulcerative colitis | Phase II | NCT04767984 | September 2021 | ||
SAHA | Advanced cancers | Phase I | NCT02042989 | June 2014 | |
Synergistic | AZD1775 | Small cell lung cancer | Phase II | NCT02688907 | June 2016 |
Advanced gastric adenocarcinoma | Phase II | NCT02448329 | January 2015 | ||
Ovarian cancer | Phase II | NCT01357161 | July 2011 | ||
Epithelial ovarian cancer | Phase II | NCT01164995 | July 2010 |
